Chronic and acute cerebrovascular pathology in patients with Ph-negative myeloproliferative diseases

Disturbances of microcirculation play a significant role in the development and progression of acute and chronic cerebrovascular diseases (CVD). One of the reasons of prothrombogenic state of the endothelium is the increase of the number of blood corpuscles leading to myeloproliferative disorders (non-Ph) (MPD). Headache was one of the most prominent clinical symptoms of CVD. It is often preceded the hematological diagnosis. Often headache is associated with focal vascular lesions on the magnetic resonance imaging. Acute cerebral events occurring as a result of thrombotic occlusion of the one or several carotid arteries tend to exhibit a fluctuating clinical course – the latter being closely linked to the dynamics of thrombus progression. Our data suggest that the decrease in vascular wall elasticity and its athrombogenic properties may lead to a pathologic change in endothelial function – consequently leading to stroke. An important clinical feature of the mentioned CVD is the young age of patients – this underlines the necessity of hematological tests in cases with cryptogenic stroke.

1. University of Washington, Institute for Health Metrics and Evaluation. GBD Compare: Global Burden of Disease data visualizations. Global, deaths, both sexes, all ages, 2010. http://vizhub.healthdata.org/gbdcompare/. Accessed July 31, 2014.

2. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation. 2015; 131(4): e29-322. doi: 10.1161/CIR.0000000000000152.

3. Shmidt E.V. Classification of vascular diseases of the brain and spinal cord. Journal of neurology and psychiatry n.a. S.S. Korsakov. Russian journal (Zhurnal Nevrologii i psihiatrii imeni Korsakova). 1985; 85(9): 1281–8.

4. Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia. 2008; 22(1): 3–13.

5. Hultcrantz M., Wilkes S.R., Kristinsson S.Y., Andersson T.M., Derolf A.R., Eloranta S., et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J. Clin. Oncol. 2015; 33(20): 2288–95. doi: 10.1200/JCO.2014.57.6652.

6. Brodmann S., Passweg J.R., Gratwohl A., Tichelli A., Skoda R.C. Myeloproliferative disorders: complications, survival and causes of death. Ann. Hematol. 2000; 79(6): 312–8.

7. De Stefano V., Za T., Rossi E., Florini A., Ciminello A., Luzzi C, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009; 94(5): 733–7.

8. Melikhyan A.L., Turkina A.G., Abdulkadirov K.M., Zaritsky A.U., Afanasiev B.V., Shuvaev V.A., et al. Clinical guidelines for the management of patients with polycythemia vera, essential thrombocytemia, primary myelofibrosis. Hematology and Transfusiology. Russian journal (Gematologiya i transfusiologiya). 2014; 59(4): 31–56.

9. Tanashyan M.M., Kuznetsova P.I., Lagoda O.V., Shabalina A.A., Subortseva I.N., Melikhyan A.L. Myeloproliferative diseases and ischemic stroke. Annals of Clinical end Experimental Neurology. Russian journal (Annaly Nevrologii). 2014; 8(2): 41–5.

10. Vannucchi A.M., Antonioli E., Guglielmelli P., Longo G., Pancrazzi A., Ponziani V., et al.; MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007; 21(9): 1952–9.

11. Melikhyan A.L., Subortseva I.N. 19-th European ssociation of hematology Congress Materials (2014, Milan). Clinical Oncohematology. Basic Research and Clinical Practice. Russian Journal (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2014; 7(4): 568–607.

12. Lussana F., Caberlon S., Pagani C., Kamphuisen P.W., Buller H.R., Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb. Res.2009; 124(4): 409–17. doi: 10.1016/j.thromres.2009.02.004.

13. Celermajer D.S. Testing endothelial function using ultrasound. J. Cardiovasc. Pharmacol. 1998; 32(3): 29–32.

14. Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol. 1957; 17(4): 237–46.

15. Blumenthal D.T., Glenn M.J. Neurological manifestation of hematological disorders. Neurol. Clin. 2002; 20(1): 265–81, viii.

16. Michiels J.J., Berneman Z., Schroyens W., Koudstaal P.J., Lindemans J., Neumann N.A. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and oumadin-resistant arterial thrombophilia. Platelets. 2006; 17(8): 528–44.

17. Edmeads J. Headache in the elderly. In: Olesen J, Tfelt-Hansen P., Welch K.M.A., eds. The headaches. 2 nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000: 947–51.

18. Fairbanks V.F., Beutler E. Iron deficiency. In: Beutler E., Lichtman M.A., Coller B.S., Kipps T.J., eds. Williams hematology. 5th ed. New York: McGraw-Hill Inc.; 1995: 490–511.

19. Ferrant A. What clinical and laboratory data are indicative of polycythemia and when are blood volume samples needed? Nouv. Rev. Fr. Hematol. 1994; 36(2): 151–4.

20. Newton L.K. Neurologic complications of polycythemia and their impact on therapy. Oncology. 1990; 4(3): 59–64.

21. Frewin R., Dowson A. Headache in essential thrombocythaemia. Int. J. Clin. Practice. 2012; 66(10): 976–83. doi: 10.1111/j.1742-1241.2012.02986.x.

22. Kesler A., Ellis M.H., Manor Y., Gadoth N., Lishner M. Neurological complications of essential thrombocytosis (ET). Acta Neurol. Scand. 2000; 102(5): 299–302.